Project leader

The Charité Universitätsmedizin, Berlin is one of the biggest and oldest University Hospitals of Europe having completed it’s 300 years in 2010. It provides ample opportunites, rich facilities, ambient atmosphere and proper guidance to young and old researchers, doctors and other medical health care personal. About half of Germany’s noble prize winners like Emil von Behring, Robert Koch and Paul Ehrlich come from this highly esteemed, internationally acclaimed University. The Charité has four campuses which harbour 100 clinical departments and institutes. There are roughly 13,200 co-workers of the Charité, and it has an annual turnover of more than one billion Euros.

The Department of Nuclear Medicine of the Charité possesses all state-of-the-art equipment required for cutting edge research and clinical practice. Researchers of the department are involved in a number of national and international collaborations and projects ranging from preclinical and translational research (bench to bedside) to phase 3 clinical studies. Main areas of scientific collaborations are in the field of oncology, endocrinology, and neuroscience. Additionally, the Department of Nuclear Medicine as certified Centre of Excellence of the European Neuroendocrine Tumor Society oversees one of the largest patient populations suffering from neuroendocrine tumors including insulinoma.   =

Prof. Dr. Winfried Brenner is the Director of the Department of Nuclear Medicine at the Charité since 2009. His academic interests are focusing on translational molecular tumor imaging, tracer biokinetics and quantitative imaging approaches, and radionuclide therapy.

Dr. Oliver Blankenstein is a world renowned expert in the field of congenital hyperinsulinism. He has been involved in establishing and optimizing F-18-DOPA-PET/CT in patients with CHI, his special interests are radio-imaging of CHI as well as  medical treatment of diffuse forms.

Vikas Prasad is the Deputy Director of the Department of Nuclear Medicine at the Charité since 2011. His major interest lies in the diagnostic and therapeutic applications of radiolabelled probes with special emphasis on neuroendocrine tumors and PET/CT.